PositiveID Corp (OTCMKTS:PSID) and GenArraytion Inc. reported that they have finalized a partnership deal. As per the agreement, they will assess GenArraytion’s assays on PositiveID Corp’s leading Firefly Dx PCR prototype system.

The product

PositiveID has designed an innovative product known as Firefly DX who offers real-time, precise diagnostic results at the point of need. The results are displayed in a handheld device. It is a unique product that does not need any lab-based equipment, which is the case with existing systems. The main features are point-of-need availability, lab-quality results, detection of pathogenic organisms, food and agricultural screening in both developing nations and domestic markets, and detection of biological agents responsible for mass destruction.

The highlights

GenArraytion’s MultiFLEX Bioassays™ contribute significantly in multiplexing flexibility. There can be up to 20 DNA/RNA samples in a single assay panel. They are highly specific, readily configurable, and sensitive assays ready to be utilized in real-time. MultiFLEX Bioassays™ are designed for veterinary disease agents, clinical pathogens, water or food-borne pathogens and other biological threats.

The management speaks

Dr. R. Paul Schaudies, the CEO of GenArraytion, said that they are quite interested in the work that PositiveID is doing with the product ‘Firefly Dx.’ It could considerably advance the scope of the real-time PCR industry. He added that they are delighted to associate with PositiveID to assess the assays on this essential and innovative point-of-need platform.

Lyle Probst, the President of PositiveID Corp (OTCMKTS:PSID), said that GenArraytion’s real-time PCR assays and competencies are first-rate, which is verified by their existing world-class client base. They believe that the cooperative experience will give company an opportunity to further boost the testing and development process of Firefly Dx.

In last trading session, the stock price of PositiveID surged 0.68% to close the trading session at $0.0295. The gains came at a share volume of 7.63 million compared to average share volume of 8.35 million.